Defective Sequencing Reagents to Cost Illumina up to $23M in 2009; Company Says Problem is Solved | GenomeWeb

By Julia Karow

This article was originally published Oct. 28.

Illumina reported last week that a defect in its paired-end sequencing reagent kits — along with stimulus funding-related order delays and a decline of whole-genome genotyping studies — caused a shortfall in its third-quarter revenues.

Revenues for the three months ended Sept. 30 totaled $158 million, $4 million less than what the company had forecast as a minimum, though they grew 5 percent over the same period in 2008.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.